NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
28 January 2022 - 10:50PM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a
pharmaceutical company focused on developing and commercializing
high-quality, scientifically formulated products for the eyecare
and skincare markets, announces the appointments of Audrey Kunin,
M.D. and Julie Garlikov to the NovaBay Board of Directors. Dr.
Kunin is a recognized leader in the skincare product industry and
has served as NovaBay’s Chief Product Officer since its acquisition
in November 2021 of DERMAdoctor, LLC, a company she cofounded. Ms.
Garlikov brings to NovaBay more than 25 years of marketing
experience, including deep expertise in health, beauty, eyecare and
dermatology products.
NovaBay also announces the resignation of Zhang Xinzhou (Paul)
Li as a director. His vacancy is being filled by Yongxiang (Sean)
Zheng. All changes to the Board of Directors are effective
immediately and result in an increase to the size of NovaBay’s
Board from six to eight members.
“This is an exciting, transformational time at NovaBay with the
recent addition of DERMAdoctor and our planned further expansion
into the large, lucrative OTC eyecare and skincare markets. We are
delighted to welcome professionals to our Board who bring highly
relevant experience and records of success,” said Paul E. Freiman,
Board Chairman. “In less than two months Audrey has proven her
leadership skills and industry knowledge, and is instrumental to
our new product strategy and the development of innovative products
for both the skincare and eyecare markets. We look forward to
calling upon Julie’s expertise and fresh ideas, particularly in
formulating effective digital and social media strategies to create
brand awareness and demand generation for our products.
“Sean has international experience in the medical device arena
and was recommended to fill our Board vacancy by several of our
large ex-US stockholders,” he added. “The Board would like to thank
Paul for his valuable contributions over his nearly seven years of
service as a director.”
“We have created a new NovaBay with the acquisition of
DERMAdoctor with revenues diversified across the eyecare and
skincare markets and a path toward profitability,” said Justin
Hall, NovaBay CEO. “With the addition of our new directors, our
Board better reflects our new direction with added industry and
marketing expertise that we expect will be highly valuable to our
success.”
Dr. Kunin has been the creative force behind all DERMAdoctor
products since 1998. At DERMAdoctor, she led the formulation and
development of numerous innovative skincare products. Dr. Kunin
graduated from Ohio State University and received her M.D. from the
Medical College of Ohio. She completed postgraduate training in
dermatology at the Medical College of Virginia after serving as
Chief Resident. She is a fellow of the American Academy of
Dermatology and formerly served as an Assistant Clinical Instructor
of Dermatology at the University of Kansas School of Medicine.
Ms. Garlikov is a classically trained consumer product goods
marketer who gained her consumer experience at Procter &
Gamble, Johnson & Johnson and PepsiCo. Since 2020 she has
served as Vice President of Marketing of GRAIL, LLC, a multi-cancer
early detection company. Prior to GRAIL she was Chief Marketing
Officer at NewAge, Inc., a healthy products company where she led
all aspects of global marketing including product development,
creative, social media, digital and branding. She previously was
Chief Marketing Officer of Shaklee Corporation and held senior
marketing positions at dermatological skincare companies Rodan +
Fields, Obagi Medical and Nuvesse Skin Therapies. Ms. Garlikov
holds a BA from the University of California, Berkeley and an MBA
from Columbia University.
Mr. Zheng brings to NovaBay more than 27 years of experience in
mergers and acquisitions, fund management and the import/export
business. He is CEO of Q3 Medical Devices (Shanghai) Co. Ltd.,
having previously held CEO and Managing Director positions at Boill
Fund Management (HK) Co., Ltd. and Sprott-Zijin Mining Fund, a
joint venture fund between Zijin Mining Group and Sprott Asset
Management LP. Mr. Zheng is a chartered financial analyst and
graduated from China’s Renmin University . He received an MBA from
the University of New South Wales in 2002, and an MA of EMBA from
China Europe International Business School in 2010.
About NovaBay Pharmaceuticals, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that
develops and sells scientifically created and clinically proven
consumer products for the eyecare and skincare markets. Avenova® is
the most prescribed antimicrobial lid and lash spray and CelleRx®
is a breakthrough product in the beauty category. In November 2021,
NovaBay acquired DERMAdoctor, LLC, a company offering more than 30
dermatologist-developed skincare products sold through traditional
domestic retailers, digital beauty channels and international
distributors.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress
Like us on Facebook Follow us on Twitter Connect with NovaBay on
LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220128005084/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Apr 2024 to May 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From May 2023 to May 2024